Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics' stock price has decreased by 43.43% over the last year as of November 26, 2025, and was down 57% over the past year by September 2, 2025. Key events include the release of Q3 2025 earnings on November 6, 2025, and Q2 2025 earnings on August 13, 2025. On August 1, 2025, the ALPHA3 study protocol was adjusted due to a Grade 5 adverse event linked to ALLO-647, leading to the closure of the arm testing fludarabine and cyclophosphamide (FC) plus ALLO-647. In Q2 2025, clinical enrollment for ALLO-329 in autoimmune indications was initiated, and updated Phase 1b cohort data for ALLO-316 was presented at ASCO, with subsequent FDA alignment on a pivotal trial design for ALLO-316 in solid tumors.

As a clinical-stage biotechnology company, Allogene Therapeutics does not have commercialized products or services subject to traditional demand seasonality. Its performance is driven by clinical trial progress, regulatory milestones, and funding activities, rather than seasonal fluctuations in product demand.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company creates "off-the-shelf" AlloCAR T™ products to address the complexities of autologous CAR T therapies. Allogene's pipeline includes AlloCAR T products like Cemacabtagene Ansegedleucel (cema-cel) for hematologic malignancies, ALLO-316 for CD70+ heme malignancies and solid tumors, ALLO-213 for small-cell lung cancer and neuroendocrine tumors, ALLO-182 for gastric and pancreatic cancer, and ALLO-329 for rheumatology disorders and autoimmune diseases.

Allogene Therapeutics is headquartered in South San Francisco, California, with R&D and manufacturing facilities in Newark, California. Its global presence is characterized by multi-center clinical trials across North America, Europe, and potentially other regions, along with global collaborations for research and technology access.

Allogene Therapeutics' brand reputation has been influenced by its clinical trial progress and challenges. The company published its inaugural ESG report in March 2022. The adjustment of the ALPHA3 trial in August 2025 due to an adverse event linked to ALLO-647 could impact reputation, but the company continues to advance its pipeline and engage with the scientific and investor communities.

Allogene Therapeutics is predominantly owned by institutional shareholders, who hold 72.13% of the company's stock, while insiders own 34.77%. Pfizer Inc. owns 22.03 million shares, representing 9.80% of the company. Other major institutional owners include TPG GP A LLC, BlackRock, Inc., Citadel Advisors Llc, SMCWX - SMALLCAP WORLD FUND INC Class A, Vanguard Group Inc, Primecap Management Co/ca/, Woodline Partners LP, and Frazier Life Sciences Management, L.P.